EP0512023A4 - Medicaments and methods for treating aids and arc employing anti-carbohydrate antibodies and carbohydrate antigens - Google Patents

Medicaments and methods for treating aids and arc employing anti-carbohydrate antibodies and carbohydrate antigens

Info

Publication number
EP0512023A4
EP0512023A4 EP19910903499 EP91903499A EP0512023A4 EP 0512023 A4 EP0512023 A4 EP 0512023A4 EP 19910903499 EP19910903499 EP 19910903499 EP 91903499 A EP91903499 A EP 91903499A EP 0512023 A4 EP0512023 A4 EP 0512023A4
Authority
EP
European Patent Office
Prior art keywords
carbohydrate
medicaments
methods
treating aids
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19910903499
Other versions
EP0512023A1 (en
Inventor
John-Erik Stig Hansen
Jens Ole Nielsen
Bent Faber Vestergaard
Henrik Clausen
Sen-Itiroh Hakomori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomembrane Institute
Original Assignee
Biomembrane Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomembrane Institute filed Critical Biomembrane Institute
Publication of EP0512023A1 publication Critical patent/EP0512023A1/en
Publication of EP0512023A4 publication Critical patent/EP0512023A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A monoclonal or other antibody to the carbohydrate antigen Tn can be used to inhibit or slow the progression of AIDS or ARC. The atigen can be used in a vaccine, for immunisation.
EP19910903499 1990-01-26 1991-01-24 Medicaments and methods for treating aids and arc employing anti-carbohydrate antibodies and carbohydrate antigens Ceased EP0512023A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47066690A 1990-01-26 1990-01-26
US470666 1990-01-26

Publications (2)

Publication Number Publication Date
EP0512023A1 EP0512023A1 (en) 1992-11-11
EP0512023A4 true EP0512023A4 (en) 1993-06-30

Family

ID=23868522

Family Applications (2)

Application Number Title Priority Date Filing Date
EP91900749A Expired - Lifetime EP0511967B1 (en) 1990-01-26 1990-12-13 Medicaments and methods for treating acquired immune deficiency syndrome (aids) and aids-related complex (arc) employing anti-carbohydrate antibodies
EP19910903499 Ceased EP0512023A4 (en) 1990-01-26 1991-01-24 Medicaments and methods for treating aids and arc employing anti-carbohydrate antibodies and carbohydrate antigens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP91900749A Expired - Lifetime EP0511967B1 (en) 1990-01-26 1990-12-13 Medicaments and methods for treating acquired immune deficiency syndrome (aids) and aids-related complex (arc) employing anti-carbohydrate antibodies

Country Status (10)

Country Link
EP (2) EP0511967B1 (en)
JP (2) JPH05506565A (en)
AT (1) ATE134649T1 (en)
AU (1) AU653141B2 (en)
CA (2) CA2074512A1 (en)
DE (1) DE69025629T2 (en)
ES (1) ES2082962T3 (en)
FI (1) FI923348A (en)
NO (1) NO922941L (en)
WO (2) WO1991011528A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044741A1 (en) * 1990-06-18 1991-12-19 Jade Chin Hiv gp120 monoclonal antibodies
JP2002530071A (en) 1998-11-13 2002-09-17 クラウセン、ヘンリク UDP galactose: β-N-acetyl-glucosamine β1,3 galactosyltransferase, β3Gal-T5
US6800468B1 (en) 1998-11-13 2004-10-05 Henrik Clausen UDP-galactose: β-N-acetyl-glucosamine β1,3galactosyltransferases, β3Gal-T5
WO2005078443A1 (en) * 2004-02-13 2005-08-25 Inverness Medical Switzerland Gmbh Determination of infection by the immune response to a carbohydrate moiety

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304663A1 (en) * 1987-07-31 1989-03-01 Japan Immuno Research Laboratories Co., Ltd. Detection method of abnormally responding lymphocytes as well as detection reagent and kit therefor
WO1989008711A1 (en) * 1988-03-11 1989-09-21 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304663A1 (en) * 1987-07-31 1989-03-01 Japan Immuno Research Laboratories Co., Ltd. Detection method of abnormally responding lymphocytes as well as detection reagent and kit therefor
WO1989008711A1 (en) * 1988-03-11 1989-09-21 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH vol. 48, no. 8, 15 April 1988, PHILADELPHIA PA, US pages 2214 - 2220 T. KJELDSEN ET AL. 'Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope.' *
THE JOURNAL OF IMMUNOLOGY vol. 142, no. 9, 1 May 1989, BALTIMORE MD, US pages 3070 - 3075 S. PINCUS ET AL. 'Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates.' *
THE JOURNAL OF VIROLOGY vol. 64, no. 6, June 1990, BALTIMORE MD, US pages 2833 - 2840 J. HANSEN ET AL. 'Inhibition of human immunodeficiency virus (HIV) infection in vitro by anti-carbohydrate monoclonal antibodies: Peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.' *

Also Published As

Publication number Publication date
DE69025629T2 (en) 1996-07-04
WO1991011528A1 (en) 1991-08-08
FI923348A0 (en) 1992-07-23
DE69025629D1 (en) 1996-04-04
WO1991011199A1 (en) 1991-08-08
EP0511967B1 (en) 1996-02-28
JPH05506565A (en) 1993-09-30
ATE134649T1 (en) 1996-03-15
NO922941L (en) 1992-09-17
EP0511967A1 (en) 1992-11-11
AU653141B2 (en) 1994-09-22
CA2074512A1 (en) 1991-07-27
JPH05506843A (en) 1993-10-07
NO922941D0 (en) 1992-07-24
FI923348A (en) 1992-07-23
CA2073459A1 (en) 1991-07-27
ES2082962T3 (en) 1996-04-01
EP0512023A1 (en) 1992-11-11
AU6961491A (en) 1991-08-21

Similar Documents

Publication Publication Date Title
NO944475L (en) Combined vaccines comprising Hepatite B surface antigen and other antigens
DE69110084D1 (en) In vitro method for the amplification of antigen specific monoclonal antibody producing human peripheral blood lymphocytes.
ES2106195T3 (en) IGG AGLYCOSILATED ANTIBODY ANTI CD3.
EP0306524A4 (en) Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens.
ZA884651B (en) Monoclonal antibody specific to hiv antigens
DK388384D0 (en) MONOCLONE ANTIBODIES WITH SPECIFICITY FOR MEMBRANE-ASSOCIATED ANTIGENS, THEIR PREPARATION AND USE
NO302176B1 (en) Process for the preparation of a monoclonal antibody and an antigen
GB8912497D0 (en) Monoclonal antibodies
IL70746A0 (en) Specific cea-family antigens,antibodies specific thereto and methods for the use thereof
EP0512023A4 (en) Medicaments and methods for treating aids and arc employing anti-carbohydrate antibodies and carbohydrate antigens
JPS6463392A (en) Monoclonal antibody against specific antigen for human immunodeficiency virus
DK140992D0 (en) PROCEDURE FOR THE PRODUCTION OF ANTIBODIES AGAINST HAPTENES AND OTHER B-CELL ANTIGENS, ANTIBODIES OBTAINED BY THE PROCEDURE AND USE OF THESE ANTIBODIES FOR THE PREPARATION OF VACCINS
GB8704648D0 (en) Antibodies
EP0307476A4 (en) Bilirubin antigen, monoclonal antibody therefor, process for their preparation, and their use
EP0537168A4 (en) Ctaa 28a32, the antigen recognized by mca 28a32
EP0319333A3 (en) Method for the prevention of graft versus host disease
EP0334076A3 (en) Monoclonal antibody capable of recognizing an antigen associated with human arteriosclerosis, and process for preparing the same
ES2013665A6 (en) Human monoclonal antibodies against rabies virus.
FR2608926B1 (en) BABESIA DIVERGENS ANTIGEN, PROCESS FOR PRODUCING THE SAME, AND VACCINE CONTAINING THE SAME
IT1254570B (en) Antigens bound to the outer surface of erythrocytes and procedure for their preparation
ATE73234T1 (en) ANTI-PARATHYROID ANTIBODY PREPARAT.
EP0672120A4 (en) Production of human monoclonal antibodies active against hepatitis b surface antigen.
GB2233559B (en) Antibodies for use in antilymphocyte antibody therapy
PL245361A1 (en) Method of obtaining antibodies specific for antigens isolated from human serum,in particular for the antigen hbs.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930511

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950518

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19960615